John Zhong

John Zhong is the President and CEO of Gencyte Therapeutics, Inc., a company focused on innovative therapies in the field of biotechnology. He is based in San Francisco, CA. His expertise encompasses CAR-T immunotherapy, cancer vaccines, and antibody/protein engineering.23

Before his current role at Gencyte, John Zhong held significant positions in the biopharmaceutical industry. He was previously the Vice President of Biometrics at REGENXBIO, where he led statistical strategies for clinical development across various therapeutic areas.1 His career also includes a role as a Biostatistics Group Head at Biogen, where he contributed to the development of treatments in immunology and rare diseases.1

John holds a PhD in Mathematical Statistics from the University of Maryland at College Park and has coauthored over 50 manuscripts in peer-reviewed journals, reflecting his extensive involvement in statistical innovation within drug development.1 His contributions to the industry include participation in FDA panels and leadership roles in developing international regulatory guidelines for adaptive clinical trials.1